Cargando…

Estimated Monetary Value of Future Research Clarifying Uncertainties Around the Optimal Adult Hearing Screening Schedule

IMPORTANCE: Adult hearing screening is not routinely performed, and most individuals with hearing loss (HL) have never had their hearing tested as adults. OBJECTIVE: To project the monetary value of future research clarifying uncertainties around the optimal adult hearing screening schedule. DESIGN,...

Descripción completa

Detalles Bibliográficos
Autores principales: Borre, Ethan D., Myers, Evan R., Dubno, Judy R., Emmett, Susan D., Pavon, Juliessa M., Francis, Howard W., Ogbuoji, Osondu, Sanders Schmidler, Gillian D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652748/
https://www.ncbi.nlm.nih.gov/pubmed/36367737
http://dx.doi.org/10.1001/jamahealthforum.2022.4065
_version_ 1784828543533842432
author Borre, Ethan D.
Myers, Evan R.
Dubno, Judy R.
Emmett, Susan D.
Pavon, Juliessa M.
Francis, Howard W.
Ogbuoji, Osondu
Sanders Schmidler, Gillian D.
author_facet Borre, Ethan D.
Myers, Evan R.
Dubno, Judy R.
Emmett, Susan D.
Pavon, Juliessa M.
Francis, Howard W.
Ogbuoji, Osondu
Sanders Schmidler, Gillian D.
author_sort Borre, Ethan D.
collection PubMed
description IMPORTANCE: Adult hearing screening is not routinely performed, and most individuals with hearing loss (HL) have never had their hearing tested as adults. OBJECTIVE: To project the monetary value of future research clarifying uncertainties around the optimal adult hearing screening schedule. DESIGN, SETTING, AND PARTICIPANTS: In this economic evaluation, a validated decision model of HL (DeciBHAL-US: Decision model of the Burden of Hearing loss Across the Lifespan) was used to simulate current detection and treatment of HL vs hearing screening schedules. Key model inputs included HL incidence (0.06%-10.42%/y), hearing aid uptake (0.54%-8.14%/y), screening effectiveness (1.62 × hearing aid uptake), utility benefits of hearing aids (+0.11), and hearing aid device costs ($3690). Distributions to model parameters for probabilistic uncertainty analysis were assigned. The expected value of perfect information (EVPI) and expected value of partial perfect information (EVPPI) using a willingness to pay of $100 000 per quality-adjusted life-year (QALY) was estimated. The EVPI and EVPPI estimate the upper bound of the dollar value of future research. This study was based on 40-year-old persons over their remaining lifetimes in a US primary care setting. EXPOSURES: Screening schedules beginning at ages 45, 55, 65, and 75 years, and frequencies of every 1 or 5 years. MAIN OUTCOMES AND MEASURES: The main outcomes were QALYs and costs (2020 US dollars) from a health system perspective. RESULTS: The average incremental cost-effectiveness ratio for yearly screening beginning at ages 55 to 75 years ranged from $39 200 to $80 200/QALY. Yearly screening beginning at age 55 years was the optimal screening schedule in 38% of probabilistic uncertainty analysis simulations. The population EVPI, or value of reducing all uncertainty, was $8.2 to $12.6 billion varying with willingness to pay and the EVPPI, or value of reducing all screening effectiveness uncertainty, was $2.4 billion. CONCLUSIONS AND RELEVANCE: In this economic evaluation of US adult hearing screening, large uncertainty around the optimal adult hearing screening schedule was identified. Future research on hearing screening has a high potential value so is likely justified.
format Online
Article
Text
id pubmed-9652748
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-96527482022-11-28 Estimated Monetary Value of Future Research Clarifying Uncertainties Around the Optimal Adult Hearing Screening Schedule Borre, Ethan D. Myers, Evan R. Dubno, Judy R. Emmett, Susan D. Pavon, Juliessa M. Francis, Howard W. Ogbuoji, Osondu Sanders Schmidler, Gillian D. JAMA Health Forum Original Investigation IMPORTANCE: Adult hearing screening is not routinely performed, and most individuals with hearing loss (HL) have never had their hearing tested as adults. OBJECTIVE: To project the monetary value of future research clarifying uncertainties around the optimal adult hearing screening schedule. DESIGN, SETTING, AND PARTICIPANTS: In this economic evaluation, a validated decision model of HL (DeciBHAL-US: Decision model of the Burden of Hearing loss Across the Lifespan) was used to simulate current detection and treatment of HL vs hearing screening schedules. Key model inputs included HL incidence (0.06%-10.42%/y), hearing aid uptake (0.54%-8.14%/y), screening effectiveness (1.62 × hearing aid uptake), utility benefits of hearing aids (+0.11), and hearing aid device costs ($3690). Distributions to model parameters for probabilistic uncertainty analysis were assigned. The expected value of perfect information (EVPI) and expected value of partial perfect information (EVPPI) using a willingness to pay of $100 000 per quality-adjusted life-year (QALY) was estimated. The EVPI and EVPPI estimate the upper bound of the dollar value of future research. This study was based on 40-year-old persons over their remaining lifetimes in a US primary care setting. EXPOSURES: Screening schedules beginning at ages 45, 55, 65, and 75 years, and frequencies of every 1 or 5 years. MAIN OUTCOMES AND MEASURES: The main outcomes were QALYs and costs (2020 US dollars) from a health system perspective. RESULTS: The average incremental cost-effectiveness ratio for yearly screening beginning at ages 55 to 75 years ranged from $39 200 to $80 200/QALY. Yearly screening beginning at age 55 years was the optimal screening schedule in 38% of probabilistic uncertainty analysis simulations. The population EVPI, or value of reducing all uncertainty, was $8.2 to $12.6 billion varying with willingness to pay and the EVPPI, or value of reducing all screening effectiveness uncertainty, was $2.4 billion. CONCLUSIONS AND RELEVANCE: In this economic evaluation of US adult hearing screening, large uncertainty around the optimal adult hearing screening schedule was identified. Future research on hearing screening has a high potential value so is likely justified. American Medical Association 2022-11-11 /pmc/articles/PMC9652748/ /pubmed/36367737 http://dx.doi.org/10.1001/jamahealthforum.2022.4065 Text en Copyright 2022 Borre ED et al. JAMA Health Forum. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Original Investigation
Borre, Ethan D.
Myers, Evan R.
Dubno, Judy R.
Emmett, Susan D.
Pavon, Juliessa M.
Francis, Howard W.
Ogbuoji, Osondu
Sanders Schmidler, Gillian D.
Estimated Monetary Value of Future Research Clarifying Uncertainties Around the Optimal Adult Hearing Screening Schedule
title Estimated Monetary Value of Future Research Clarifying Uncertainties Around the Optimal Adult Hearing Screening Schedule
title_full Estimated Monetary Value of Future Research Clarifying Uncertainties Around the Optimal Adult Hearing Screening Schedule
title_fullStr Estimated Monetary Value of Future Research Clarifying Uncertainties Around the Optimal Adult Hearing Screening Schedule
title_full_unstemmed Estimated Monetary Value of Future Research Clarifying Uncertainties Around the Optimal Adult Hearing Screening Schedule
title_short Estimated Monetary Value of Future Research Clarifying Uncertainties Around the Optimal Adult Hearing Screening Schedule
title_sort estimated monetary value of future research clarifying uncertainties around the optimal adult hearing screening schedule
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652748/
https://www.ncbi.nlm.nih.gov/pubmed/36367737
http://dx.doi.org/10.1001/jamahealthforum.2022.4065
work_keys_str_mv AT borreethand estimatedmonetaryvalueoffutureresearchclarifyinguncertaintiesaroundtheoptimaladulthearingscreeningschedule
AT myersevanr estimatedmonetaryvalueoffutureresearchclarifyinguncertaintiesaroundtheoptimaladulthearingscreeningschedule
AT dubnojudyr estimatedmonetaryvalueoffutureresearchclarifyinguncertaintiesaroundtheoptimaladulthearingscreeningschedule
AT emmettsusand estimatedmonetaryvalueoffutureresearchclarifyinguncertaintiesaroundtheoptimaladulthearingscreeningschedule
AT pavonjuliessam estimatedmonetaryvalueoffutureresearchclarifyinguncertaintiesaroundtheoptimaladulthearingscreeningschedule
AT francishowardw estimatedmonetaryvalueoffutureresearchclarifyinguncertaintiesaroundtheoptimaladulthearingscreeningschedule
AT ogbuojiosondu estimatedmonetaryvalueoffutureresearchclarifyinguncertaintiesaroundtheoptimaladulthearingscreeningschedule
AT sandersschmidlergilliand estimatedmonetaryvalueoffutureresearchclarifyinguncertaintiesaroundtheoptimaladulthearingscreeningschedule